Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 18/20 | 0.76 |
| ▸ | IRAK2 | O43187 | 1/20 | 0.76 |
| ▸ | CLK1 | P49759 | 1/20 | 0.76 |
| ▸ | CLK2 | P49760 | 1/20 | 0.76 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.76 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.76 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.76 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.76 |
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21069405 | 1.00 | IRAK4 (0.76) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21106847 | 1.00 | IRAK4 (0.76) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21106437 | 0.89 | IRAK4 (0.78) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21069630 | 0.89 | IRAK4 (0.78) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL24379901 | 0.89 | IRAK4 (0.78) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL26528553 | 0.89 | IRAK4 (0.73) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23763239 | 0.86 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21106962 | 0.86 | IRAK4 (0.73) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL23860570 | 0.86 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 | |
| SCHEMBL21106082 | 0.86 | IRAK4 (1.00) | IRAK4IRAK2CLK1CLK2IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885IRAK2 1/4885CLK1 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.